

Resource Summary Report

Generated by ASWG on Aug 8, 2026

APC anti-mouse CD3

RRID:AB_2561455

Type: Antibody

Proper Citation

BioLegend Cat# 100235, RRID:AB_2561455

Antibody Information

URL: http://antibodyregistry.org/AB_2561455

Proper Citation: BioLegend Cat# 100235, RRID:AB_2561455

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2561455

Vendor: BioLegend

Catalog Number: 100235

Alternative Catalog Numbers: 100236

Record Creation Time: 20250820T024500+0000

Record Last Update: 20250820T142515+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD3.

No alerts have been found for APC anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 75 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

de Lima J, et al. (2026) HIF-1⁺ CD4⁺ T cells coordinate a tissue-resident immune cell network in the lung. *Immunity*, 59(4), 1092.

Selvaratnam JS, et al. (2026) HEB collaborates with TCR signaling to upregulate Id3 and enable $\gamma\delta$ T17 cell maturation in the fetal thymus. *eLife*, 14.

Ledwith AE, et al. (2026) Yeast β -glucan supplementation supports immunometabolic anti-tumor responses and reverses obesity-induced dysfunction via trained hematopoiesis. *Cell reports*, 45(7), 117648.

Zhang L, et al. (2026) Bcl11a orchestrates multilineage integrity in aging hematopoiesis by regulating multipotent progenitor fate decisions. *Cell reports*, 45(7), 117716.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Chen M, et al. (2026) Nano-granulated zoledronate sensitizes innate immune metabolism to enhance vaccine-induced and antitumor immunity. *Cell reports. Medicine*, 7(5), 102765.

Li X, et al. (2026) Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. *Cell*, 189(3), 853.

Matoba K, et al. (2026) Circulating extracellular vesicle microRNAs mediate immune modulation of social behavior in male mice. *Nature communications*, 17(1).

Fan Z, et al. (2026) Programmable-bacteria-macrophage backpacks for enhanced solid tumor therapy via mechanobiological interplay. *Cell reports. Medicine*, 102924.

Zuo B, et al. (2026) Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. *Cell reports. Medicine*, 102933.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Cohen SJ, et al. (2025) Liver microbial DNA signatures and extracellular vesicle epitopes as predictors of post-hepatectomy liver failure. *iScience*, 28(10), 113618.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Emelianov EA, et al. (2025) Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. *International journal of molecular sciences*, 27(1).

Mengrelis K, et al. (2025) IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. *Cells*, 14(14).

Young RE, et al. (2025) Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes. *Developmental cell*.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. *Cell reports. Medicine*, 6(5), 102092.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.